

# VIMOVO & DUEXIS

*Addressing an Unmet Medical Need*

## NSAID-Induced GI Toxicity

- **GI intolerance incidence: up to 50%<sup>(1)</sup>**
- **Endoscopic ulcers incidence: 15-46%<sup>(2)</sup>**
- **Leads to 107K hospitalizations and 16.5K deaths per year<sup>(3)</sup>**

## Poor Physician and Patient Compliance

- **76% of MDs do not prescribe concomitant GI therapy<sup>(4)</sup>**
- **61% of patients non-compliant by the 3rd prescription<sup>(5)</sup>**

***Novel, proprietary formulations of two of the most prescribed NSAIDs combined with a GI protectant in a single pill***

**Vimovo**  
(naproxen/esomeprazole magnesium)  
375/20+500/20 mg delayed-release tablets

VIMOVO		DUEXIS
Naproxen	NSAID	Ibuprofen
Esomeprazole magnesium (PPI)	GI Protectant	Famotidine (H <sub>2</sub> antagonist)
BID	Dosing	TID



(1) Singh and Rosen Ramey. J Rheumatol. 1998;51(suppl):8-16.

(2) Geis et al. J Rheumatol. 1996;18:11-14

(3) M.Wolfe, et.al.; Gastrointestinal Toxicity of Nonsteroidal Anti-inflammatory Drugs; NEJM; vol. 340; no. 24; June 1999.

(4) BMC Musculoskeletal Disorders 2006, 7:79

(5) Sturkenboom, et.al.; Aliment Pharmacol Ther 2003; 18:1137-1147